Objective: Epstein -Barr virus-positive diffuse large B-cell lymphoma is a provisional entity in the 2008 World Health Organization classification of tumors of hematopoietic and lymphoid tissues. Reports on the characteristics and clinical outcome of this disease in different geographic regions showed great disparities. Methods: To define the clinical characteristics as well as the prognostic impact of EpsteinBarr virus infection on diffuse large B-cell lymphoma in Taiwan, we retrospectively investigated the Epstein -Barr virus status of 89 patients with newly diagnosed diffuse large B-cell lymphoma in our institute. Results: Using a cutoff point of positive nuclear staining of Epstein -Barr virus-encoded RNA-1-in situ hybridization in !20% of the examined cells, we identified 15 cases (16.9%) of the entire study cohort as Epstein -Barr virus-positive diffuse large B-cell lymphoma. The clinical and laboratory features were not different between Epstein -Barr virus-positive and -negative diffuse large B-cell lymphoma patients. Univariate analysis showed patients with diffuse large B-cell lymphoma that were either Epstein -Barr virus-positive or had activated B-cell-like features had an inferior overall survival. Older age, advanced stage and lymphoma with activated B-cell-like features or Epstein -Barr virus-encoded RNA positivity were independent prognostic factors affecting overall survival on multivariate analysis. Patients with two or three of these adverse-risk factors were considered high risk and fared far worse than patients with no or only one adverse factor. Conclusions: Taken together, we demonstrated that a higher frequency of Epstein -Barr virus association was detected in a Taiwanese cohort of diffuse large B-cell lymphoma patients, and Epstein -Barr virus-encoded RNA positivity was shown to add important prognostic value in these patients.
INTRODUCTION
Greater than 90% of the world's population is infected by Epstein -Barr virus (EBV) and a wide variety of cancers are reported to be associated with this viral infection (1) . EBV preferentially infects B lymphocytes and has the unique ability to transform resting B cells into lymphoblastoid cell lines (2) , although it does occasionally lead to clonal proliferation of natural killer (NK) or T cells (1) . EBV has been implicated in the development of many B-cell lymphoproliferative disorders, including Burkitt's lymphoma, classic Hodgkin lymphoma and lymphoma arising in immunocompromised individuals (post-transplant and HIV-associated lymphoproliferative disorders), as well as some T-cell-associated lymphomas (3, 4) .
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma (NHL) and accounts for 30% of all newly diagnosed cases (5) . In spite of being readily curable, DLBCL has become increasingly recognized as a heterogeneous group of disease that has a wide range of immunologic features, genetic characteristics and clinical outcomes (5) . Studies in Japan first identified a potential link of EBV infection in a subset of DLBCL patients (6, 7) . Subsequently, the 2008 World Health Organization classification of tumors of hematopoietic and lymphoid tissues recognized a new provisional entity designated as EBV-positive DLBCL of the elderly (8) . The incidence of this subtype of lymphoma varies significantly in different geographic areas, but generally accounts for ,10% of all DLBCL cases and is rare among Western populations (9) . Unlike other types of EBV-associated lymphomas, this entity is unique in that it affects patients with no known immunodeficiency. EBV-positive DLBCL of the elderly, as the name suggests, has a predilection for the elderly (.50 years of age). The median age is 70 years, with 20 -25% of these patients are older than 90 years of age, and there is a slight male predominance (9) . Other clinical features at presentation are variable. Studies focusing on EBV-positive DLBCL suggest that these patients are usually associated with more advanced stages, higher incidence of extranodal involvement, a higher International Prognostic Index (IPI) risk score, the presence of B symptoms, and a worse outcome to initial treatment. Of note, most of these studies were observational and retrospective, and there was considerable diversity in the treatment modalities used in these patients, especially with respect to the incorporation of the monoclonal antibody rituximab as the core of combination chemoimmunotherapy.
A recent study has provided the first glimpse of the clinical, as well as the pathologic characteristics of EBV-positive DLBCL in Taiwan (10) . The report evaluated, for the first time, the prevalence of this DLBCL subtype in Taiwan and systemically delineated the clinicopathological significance. To provide thorough and more detailed information on EBV-positive DLBCL in Taiwan, we therefore conducted this study to evaluate the clinical characteristics and prognostic indication of EBV infection in patients with DLBCL.
PATIENTS AND METHODS

STUDY POPULATION
All patients with pathologically confirmed DLBCL diagnosed between 2003 and 2013 at our institute were screened. Only immunocompetent patients with adequate paraffin-embedded biopsy specimens for immunohistochemical (IHC) staining or EBV-encoded RNA-1 (EBER-1) and EBER-2 in situ hybridization (ISH) were included. Information on a variety of clinical characteristics, including patient demographics, results of baseline hemograms and biochemical tests, types of therapy, treatment outcomes and survival status, was obtained. The study was approved by the Institutional Review Board of Chang-Gung Memorial Hospital (Taiwan) in accordance with the Declaration of Helsinki.
HISTOLOGY, IHC STAINING AND ISH
The diagnosis of DLBCL in all pathologic specimens was confirmed and reviewed by at least two hematologists/hematopathologists with expertise at our institute. IHC staining was performed as previously reported (11) . Primary antibodies against CD10 (Dako, Carpinteria, CA, USA), bcl-6 (Dako) and MUM-1 (Dako) were used at dilutions of 1/100, 1/10 and 1/50, respectively. A high-sensitivity diaminobenzidine (DABþ) chromogenic substrate system, EnVision TM reagent (Dako), containing a peroxidase-conjugated polymer backbone and a secondary antibody molecule directed against mouse immunoglobulin, was used for detection. With these markers, we then applied Hans' model and subcategorized DLBCL into germinal cell B-cell (GCB) and activated B-cell (ABC) subtypes (12) .
For EBV detection, we performed ISH using a fluorescein isothiocyanate (FITC)-conjugated EBV peptide nucleic acid (PNA) probe and PNA ISH detection kit (Dako) following the manufacturer's protocol. The FITC-conjugated probe detects the two nuclear RNA transcripts (EBER-1 and EBER-2) encoded by EBV. We used an EBV-positive nasopharyngeal carcinoma (NPC) specimen as a positive control. To clarify the association between DLBCL and EBV, we defined the specimen with positive EBER nuclear staining in .20% of the examined cells as EBV-positive DLBCL. Representative slides of positive and negative staining on ISH studies are shown in Fig. 1 .
THERAPY AND OUTCOME
Immunochemotherapy consisted of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) as the major modality of treatment. Seven patients were treated without anthracycline (R-COP) because of advanced age, fragile health and/or personal preference. Fourteen patients were not given rituximab because the monoclonal antibody had not been reimbursed by the National Health Insurance of the Taiwanese government until 2004. Eight patients received best supportive care only. The response to treatment was assessed according to standard response criteria (13) . Overall survival (OS) was measured from the date of diagnosis until death from any cause, with observation ending at the date of last contact for patients last known to be alive.
STATISTICAL ANALYSIS
The Mann -Whitney test was used for continuous variables versus categorical variables. For comparison of the dichotomous variables, a two-sided Fisher's exact test was applied. The variables of OS were estimated by the Kaplan -Meier method. Differences between groups were calculated using the log-rank test for univariate analysis. Cox's proportional hazards model was used for multivariate analysis to test independent prognostic factors on survival outcome. All calculations were performed using the Statistical Package of Social Sciences software (version 17.0; SPSS, Inc., Chicago, IL, USA). The level of statistical significance was set at 0.05 for all tests.
RESULTS
RESULTS OF EBER ISH ON DLBCL SPECIMENS AND CLINICAL CHARACTERISTICS OF THE PATIENTS
We identified 106 immunocompetent patients with pathologically confirmed DLBCL diagnosed during the past decade at our institute. Among them, 89 patients had sufficient paraffin-embedded biopsy specimens for IHC and EBER ISH studies and were included in the current analysis. EBER positivity was identified in 15 (16.9%) of the study cohort. Of the 15 patients with EBV-positive DLBCL, only 3 had pure nodal diseases, while the other 12 (80%) had at least one extranodal site involved. The gastrointestinal (GI) tract was the most commonly involved extranodal site, as six patients (40%) had GI tract lymphomas, four of which were located in the stomach. Table 1 summarizes a comparison of the clinical and laboratory features between patients subcategorized as EBV(2) DLBCL and EBV(þ) DLBCL. There were no significant differences between the two subgroups of patients with respect to patient characteristics, including age, gender and performance status. Baseline hemograms, biochemical tests (including serum albumin, uric acid and lactate dehydrogenase levels), as well as disease-associated characteristics (Ann Arbor stage, extranodal involvement^2 sites, and international prognostic index score) were not different, either. The distributions of DLBCL subtypes (either ABC or GCB) were similar between the two groups, with the ABC DLBCL being the predominant subtype in both (63.1 and 72.7% for EBV-negative and -positive DLBCL patients, respectively; P ¼ 0.737).
TREATMENT AND SURVIVAL OUTCOME ANALYSIS There were no apparent disparities in the distribution of primary treatment modalities with respect to the use of rituximab or anthracycline between the EBV(þ) and EBV(2) groups (Table 1) . For patients in whom treatment responses were available, the overall response rate to initial therapy was 85.5% for patients with EBV(2) DLBCL and 83.3% for patients with EBV(þ) DLBCL (P ¼ 1.000). Based on univariate analysis, we evaluated several factors with respect to the impact on OS (Table 2 ). We found that older age (.60 years), poor performance status, advanced stages of disease, a pre-treatment serum albumin level ,3 g/dl, not incorporating rituximab or anthracycline during initial therapy, and a histological subtype of ABC DLBCL all adversely affected the OS. EBER positivity did not have significant impact on OS ( Fig. 2A) . We noted that the survival curves of patients with ABC DLBCL and patients with EBV-positive DLBCL nearly completely overlapped when these curves were plotted together by subdividing patients into three groups (ABC, EBV(þ), and GCB; Fig. 2B ), and the former two groups of patients fared worse than the patients with GCB DLBCL. Therefore, we considered these two groups of patients as having a similar risk of death and recategorized them together. Patients with ABC features or EBV-positive DLBCL had a far 
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EBV-positive diffuse large B-cell lymphoma in Taiwan worse OS than patients with GCB DLBCL (median PFS, 28.0 months vs. not reached; P ¼ 0.019; Table 2 and Fig. 2C ). The results indicate that ABC features and EBER positivity impose an adverse impact on OS in patients with DLBCL. Previous reports have shown that CD30 overexpression is more likely to occur in patients with EBV-positive DLBCL and CD30 co-expression with EBER portends a poor prognosis (6, 14, 15) ; however, in our EBV-positive DLBCL patient cohort, 10 patients had relevant data available and only one patient (10%) co-expressed CD30. The incidence of CD30 positivity in our EBV-negative DLBCL patients was also quite low [8 of 45 cases (17.8%)], and the difference was not statistically significant when comparing EBV-positive and EBV-negative patient populations (P ¼ 1.000). The status of CD30 expression did not have any impact on the survival outcome of our entire DLBCL cohort (P ¼ 0.112; data not shown). Because only one patient co-expressed CD30 and EBER, we did not perform further analysis on the potential effects of CD30 overexpression on the survival outcome in patients with EBV-positive DLBCL.
MULTIVARIATE ANALYSIS ON SURVIVAL OUTCOME To test various parameters of possible prognostic value, we performed multivariate analysis to examine the potential interaction and effects on OS. All seven factors of clinically significant importance on univariate analysis were included in the Cox model for comparison, and three factors were found to independently predict an inferior OS ( 
RISK STRATIFICATION FOR DLBCL PATIENTS
Considering older age, advanced disease stage, and ABC-or EBV-positive DLBCL subtypes as the three major parameters that were strongly and independently associated with an adverse OS outcome, we stratified our DLBCL patients based on the number of risk factors identified at the time of diagnosis Fig. 3 . A shows the Kaplan -Meier estimated OS curves of four risk groups of patients. DLBCL patients with 0 or only 1 risk factor fared significantly better than patients with 2 or 3 risk factors (P ¼ 0.000, log-rank test; Fig. 3A) . We further categorized patients with 0 or only 1 adverse factor as low risk and patients with 2 or 3 adverse factors as high risk. Low-risk patients had a 5-year probability of survival approaching 90%, while the medium OS for high-risk patients was 19.6 months (P ¼ 0.000, log-rank test; Fig. 3B ). 
DISCUSSION
Since the initial description of patients with EBV-positive DLBCL from Japan at the turn of the century (6,7), the disease entity has gained broader recognition worldwide as several reports from different geographic areas have described the characteristics and clinical phenotypes of this lymphoma subtype (9,10,14-23 .51%, respectively. The ageing index is much higher in our locale, suggesting that more elderly people live alone without descendants. These data indicate that patients from our locale are older and less well taken care of. As a result, the elderly people are more likely to be immunocompromised. This possibly explains the extraordinary high incidence of EBV-positive DLBCL in our community. Several previous reports have shown that patients with EBV-positive DLBCL tend to be older, present with an ABC-like immunophenotype, have more extranodal manifestations, and more aggressive clinical features (9, 16, 19, 20) ; however, the baseline characteristics did not differ between EBV-positive and -negative DLBCL in our patient cohort. The results confirm findings from a recent study that reported the largest Western population of DLBCL patients (n ¼ 732) treated with standard immunochemotherapy R-CHOP (15). The aforementioned report by Chang et al. (10) from Taiwan had similar findings, although only patient age, gender and presentation site were included in the analysis of baseline characteristics. Interestingly, there are huge discrepancies among the reported incidences of extranodal involvement in patients with EBV-positive DLBCL from different geographic regions. Extranodal presentation involving at least two sites occurred in approximately one-third to one-half of the Asian patients with EBV-positive DLBCL who were studied (10, 19, 21) , which is in agreement with the findings in our cohort (57.1%, Table 1 ). In contrast, the corresponding values were 0% (0/13), 3.6% (1/28) and 15.4% (4/28) from Western countries (15, 16, 18) . The difference might result from the discrepant frequencies of extranodal involvement in all DLBCL patients from different regions, as the percentages were higher 
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EBV-positive diffuse large B-cell lymphoma in Taiwan in Asian patients (37.1% in our study and 61.7% in the study of Chang et al 10.) than in Caucasian patients (21%) (15) . These data suggest that, rather than being an EBV-endued unique clinical phenotype, the various frequencies of extranodal involvement in different geographic areas could be related to disease characteristics underlying the pathogenesis of the entire DLBCL spectrum that are further stratified by various host factors and ethnic background. With respect to treatment response and survival outcome, several previous reports have shown that patients with EBV-positive DLBCL have an inferior clinical outcome than their counterparts (10, 16, 19, 21, 22, 24) ; however, most of the patients included in these reports received combination chemotherapy only at a time when immunotherapy (i.e. rituximab) was not universally available. When combination immunochemotherapy (R-CHOP) was used as the main therapeutic modality, there were no longer any significant differences in the survival outcome between patients with EBV-positive and -negative DLBCL (15, 26) , suggesting an especially critical role of the monoclonal antibody, rituximab, in those EBV-infected patients. About three-fourths of our entire DLBCL patient cohort received rituximab as an integral part of their treatment, and the percentage was not statistically different between EBV-positive and -negative groups. Patients with EBV-positive DLBCL appeared to have a shorter OS (median, 17.7 months vs. not reached in EBV-negative Figure 2 . Kaplan -Meier estimates of overall survival (OS) for DLBCL patients according to (A) EBV status and (B) histologic subtypes (GCB, germinal center B-cell like; and ABC, activated B-cell like) and EBER positivity (log-rank test). Patients with GCB DLBCL had significantly better OS than the other two groups of patients did. Noteworthily, the survival curves of patients with ABC DLBCL and EBV-positive DLBCL almost completely overlapped with each other. By subcategorizing them as a group and comparing them to patients with GCB DLBCL, the difference in OS was more significant (C). DLBCL), but the difference was not statistically significant (P ¼ 0.276, Table 2 and Fig. 2A ). The median OS of 17.7 months in our EBV-positive DLBCL seemed to be better than that seen in several previous reports which included patients receiving CHOP chemotherapy only (9, 10, 16, 19) . This probably suggested the importance of rituximab-containing combination treatment. In a recent study, Sato et al. (24) reported the clinical outcome of EBV positivity in a Japanese cohort of 260 DLBCL patients. Contrary to our work, they showed that the presence of EBV in DLBCL per se was an independent adverse-risk factor affecting OS outcome, in spite the fact that all of their eight EBV-positive cases included in the survival analysis were treated with rituximab-based immunochemotherapy. The reason of discrepant results between this report and others (15,26) (including ours) was not immediately clear, but racial differences might have played some roles. Interestingly, when we divided our patients into three groups by subcategorization according to GCB/ABC immunophenotypes or EBV positivity, we found that patients with EBV-positive DLBCL had an OS outcome almost identical to patients with ABC DLBCL (Fig. 2B) . Importantly, by restratifying patients with ABC features or EBV positivity into the same risk group, we clearly demonstrate that they had a significantly inferior OS outcome than patients with GCB DLBCL. When including several potential prognostic factors into multivariate analysis on OS, we found that only age .60 years, advanced Ann Arbor stage, and ABC-like immunophenotype or EBV-positivity adversely influenced the survival outcome with statistical significance (Table 3) . We recategorized our patients in two ways based on the presence of these factors. Figure 3A shows the Kaplan -Meier survival curves of patients with a different number of adverse-risk factors. Patients with zero risk factor enjoyed 100% long-term survival, while patients with 2 or 3 risk factors did very poorly, with a median survival ,30 and 10 months, respectively. When dividing our patients into low risk (with 0 or 1 adverse factor) and high-risk (with 2 or 3 adverse factors) groups, there was a dramatic dip on the OS curve for those high-risk DLBCL patients (Fig. 3B) .
In spite of systemically providing invaluable information regarding EBV-positive DLBCL in Taiwan, our study was nevertheless limited in several aspects. As mentioned earlier, our hospital is based in a community which has the highest ageing index and constitutes the most elderly population (.65 years of age) in Taiwan. Because EBV-positive DLBCL increases with age and gradual immunosenescence, our report may be biased and might not be fully representative of our country. Furthermore, it was a retrospective study with an insufficient number of cases for more precise prediction of prognosis in patients with EBV-positive DLBCL. Our study also failed to provide information on the relationship between plasma EBV DNA load and treatment outcomes in these patients, and on the utility in long-term follow-up as well as detection of recurrent lymphoma, like studies in patients with NPC (27, 28) . Future prospective and randomized clinical trials involving a large number of uniformly treated EBV-positive DLBCL patients are needed to better define this subgroup of disease and delineate the clinical usefulness of EBV DNA quantification in these patients.
In conclusion, our study has demonstrated that in our DLBCL patients, EBER positivity does not contribute to unusual clinical and laboratory features and does not have an impact on survival outcomes as a single prognostic factor. On further stratifying ABC-like or EBV-positive DLBCL as a group, however, we showed that this subcategorization in combination with old age and advanced stage forms three independent prognostic indicators that powerfully predict a dismal survival outcome in patients with DLBCL.
